Federal Circuit upholds CorMedix's MINOCIN patents; Nexus generic barred from market

CorMedix Inc.

Federal Circuit affirmed district court: Nexus generic minocycline infringes two CorMedix patents, invalidity rejected.
Permanent injunction upheld barring Nexus from marketing generic before patent expiration.
Patents are FDA Orange Book listed covering MINOCIN for Injection, used for serious infections.
CEO Joseph Todisco: ruling validates strength of MINOCIN IP portfolio and protects innovation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.